Disease · MONDO_0005439
Comparisons in its trials25
Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.
1 to 20 of 25
Download this page as JSON| Comparison | Group 1, with the outcome | Group 2, with the outcome | Participants | Trial | Source |
|---|---|---|---|---|---|
| Inclisiran vs Placebo: deaths from any cause | 1 of 241 | 1 of 240 | 481 | NCT03397121 | Trial comparisons |
| Inclisiran vs Placebo: serious adverse events | 18 of 241 | 33 of 240 | 481 | NCT03397121 | Trial comparisons |
| PF--04950615 vs Placebo: serious adverse events | 24 of 185 | 22 of 185 | 370 | NCT01968980 | Trial comparisons |
| Obicetrapib 10 mg vs Placebo: deaths from any cause | 3 of 234 | 2 of 118 | 352 | NCT05425745 | Trial comparisons |
| Obicetrapib 10 mg vs Placebo: serious adverse events | 13 of 234 | 8 of 118 | 352 | NCT05425745 | Trial comparisons |
| Enlicitide Decanoate vs Placebo: Number of Participants With Adverse Events (AEs) | 157 of 202 | 77 of 101 | 303 | NCT05952869 | Trial comparisons |
| Enlicitide Decanoate vs Placebo: deaths from any cause | 1 of 202 | 0 of 101 | 303 | NCT05952869 | Trial comparisons |
| Enlicitide Decanoate vs Placebo: Number of Participants Who Discontinued Study Drug Due to an AE | 4 of 202 | 3 of 101 | 303 | NCT05952869 | Trial comparisons |
| Enlicitide Decanoate vs Placebo: serious adverse events | 9 of 202 | 4 of 101 | 303 | NCT05952869 | Trial comparisons |
| Alirocumab 75 mg/up to 150 mg vs Placebo: serious adverse events | 10 of 167 | 7 of 81 | 248 | NCT01709500 | Trial comparisons |
| EvoMab 420 mg SC QM vs Placebo SC QM: deaths from any cause | 0 of 105 | 0 of 53 | 158 | NCT02392559 | Trial comparisons |
| EvoMab 420 mg SC QM vs Placebo SC QM: serious adverse events | 1 of 104 | 0 of 53 | 157 | NCT02392559 | Trial comparisons |
| Mipomersen vs Placebo: serious adverse events | 6 of 83 | 2 of 41 | 124 | NCT00706849 | Trial comparisons |
| MGL-3196 vs Placebo: deaths from any cause | 0 of 78 | 0 of 38 | 116 | NCT03038022 | Trial comparisons |
| MGL-3196 vs Placebo: serious adverse events | 0 of 78 | 1 of 38 | 116 | NCT03038022 | Trial comparisons |
| Alirocumab 150 Q2W vs Placebo Q2W: serious adverse events | 10 of 72 | 4 of 35 | 107 | NCT01617655 | Trial comparisons |
| Participants Previously Exposed to Alirocumab in Parent Study vs Placebo Participants in Parent Study: deaths from any cause | 0 of 46 | 0 of 12 | 58 | NCT01576484 | Trial comparisons |
| Participants Previously Exposed to Alirocumab in Parent Study vs Placebo Participants in Parent Study: serious adverse events | 8 of 46 | 4 of 12 | 58 | NCT01576484 | Trial comparisons |
| Part 1 - Inclisiran vs Part 1 - Placebo: Proportion of Subjects With ≥30% LDL-C Reduction of From Baseline at Day 150 | 6 of 34 | 3 of 18 | 52 | NCT03851705 | Trial comparisons |
| Mipomersen vs Placebo: serious adverse events | 2 of 34 | 1 of 17 | 51 | NCT00607373 | Trial comparisons |
diseases-2026-09-18-0.1.0
Sources 6
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- NLM's MeSHNLM's terms
- Open TargetsCC0 1.0
- PubMedNLM's terms
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- NLM's MeSHNLM's
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/diseases/v1/MONDO_0005439/comparisons